BR112021025179A2 - Antagonistas 5 ht2 tricíclicos - Google Patents

Antagonistas 5 ht2 tricíclicos

Info

Publication number
BR112021025179A2
BR112021025179A2 BR112021025179A BR112021025179A BR112021025179A2 BR 112021025179 A2 BR112021025179 A2 BR 112021025179A2 BR 112021025179 A BR112021025179 A BR 112021025179A BR 112021025179 A BR112021025179 A BR 112021025179A BR 112021025179 A2 BR112021025179 A2 BR 112021025179A2
Authority
BR
Brazil
Prior art keywords
tricyclic
relates
antagonists
compounds
treatment
Prior art date
Application number
BR112021025179A
Other languages
English (en)
Inventor
Lars Pettersson
Original Assignee
Anamar Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anamar Ab filed Critical Anamar Ab
Publication of BR112021025179A2 publication Critical patent/BR112021025179A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

antagonistas 5-ht2 tricíclicos. a presente invenção se refere a derivados tricíclicos de 1 amidino 4 metil [2,3 fundido] 2 pirrolina da fórmula geral (i). a invenção refere se especificamente a tais derivados que exibem atividade antagonista em relação aos receptores 5 ht2b da serotonina. a presente invenção também se refere ao uso dos ditos compostos como um medicamento e para o tratamento de fibrose, doenças cardiovasculares, dor, dii, doenças inflamatórias e câncer, bem como composições farmacêuticas que compreendem um ou mais dos ditos compostos e métodos de tratamento.
BR112021025179A 2019-06-18 2020-06-16 Antagonistas 5 ht2 tricíclicos BR112021025179A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19180740.3A EP3753924A1 (en) 2019-06-18 2019-06-18 New tricyclic 5-ht2 antagonists
PCT/EP2020/066627 WO2020254322A1 (en) 2019-06-18 2020-06-16 New tricyclic 5-ht2 antagonists

Publications (1)

Publication Number Publication Date
BR112021025179A2 true BR112021025179A2 (pt) 2022-02-01

Family

ID=66951850

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025179A BR112021025179A2 (pt) 2019-06-18 2020-06-16 Antagonistas 5 ht2 tricíclicos

Country Status (11)

Country Link
US (1) US20220267268A1 (pt)
EP (2) EP3753924A1 (pt)
JP (1) JP2022537528A (pt)
KR (1) KR20220023982A (pt)
CN (1) CN114616224A (pt)
AU (1) AU2020295685A1 (pt)
BR (1) BR112021025179A2 (pt)
CA (1) CA3141747A1 (pt)
IL (1) IL288514A (pt)
MX (1) MX2021015526A (pt)
WO (1) WO2020254322A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11952378B1 (en) * 2023-12-14 2024-04-09 King Faisal University Pyrrolo[2,3-c]isoquinoline-1,2-dione compounds as CK2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103839D0 (en) * 1991-02-23 1991-04-10 Smithkline Beecham Plc Pharmaceuticals
ES2250667T3 (es) * 2001-07-13 2006-04-16 PHARMACIA & UPJOHN COMPANY LLC Hexahidroazepino(4,5-g)indoles e indolinas como ligandos del receptor 5-ht.
ATE544750T1 (de) * 2001-09-21 2012-02-15 Bristol Myers Squibb Co Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer
WO2005080322A1 (ja) 2004-02-20 2005-09-01 Astellas Pharma Inc. フルオレン誘導体
KR20080094962A (ko) 2006-02-20 2008-10-27 아스텔라스세이야쿠 가부시키가이샤 아미드 유도체 또는 그의 염
CN101910157B (zh) * 2007-11-16 2014-05-07 纽尔亚商股份有限公司 吲哚化合物和治疗内脏痛的方法
CA2741511C (en) 2008-11-21 2017-01-24 Raqualia Pharma Inc. Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity
EP3109237A1 (en) * 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists

Also Published As

Publication number Publication date
WO2020254322A1 (en) 2020-12-24
EP3986865A1 (en) 2022-04-27
CN114616224A (zh) 2022-06-10
AU2020295685A1 (en) 2021-12-23
IL288514A (en) 2022-01-01
US20220267268A1 (en) 2022-08-25
CA3141747A1 (en) 2020-12-24
KR20220023982A (ko) 2022-03-03
EP3753924A1 (en) 2020-12-23
JP2022537528A (ja) 2022-08-26
MX2021015526A (es) 2022-02-03

Similar Documents

Publication Publication Date Title
CL2022002828A1 (es) Inhibidores de kras tricíclicos fusionados.
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
NZ747259A (en) Soluble c5ar antagonists
EA033497B1 (ru) 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
TW200736189A (en) Indene derivatives, their preparation and use as medicaments
BR112016004023A2 (pt) Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201001181A1 (ru) ЗАМЕЩЕННЫЕ ЦИКЛОАЛКАНО[e ИЛИ d]ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
BRPI0821266B8 (pt) Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica
AR080871A1 (es) Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa
BR112021019256A2 (pt) Moduladores de receptor x4 de proteína g relacionado a mas e produtos e métodos relacionados
CY1117826T1 (el) Ενωσεις μορφiνανης
BR112015021534A2 (pt) composto, e, composições farmacêuticas
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
BR112021011325A2 (pt) Derivados de rapamicina
BR112022004925A2 (pt) Composto, isômero do mesmo, solvato do mesmo, hidrato do mesmo ou sal farmaceuticamente aceitável do mesmo, método de preparação, uso do dito composto e composição farmacêutica
MX2018009458A (es) Derivado de sulfonamida heterociclico y medicina que contiene el mismo.
PH12021550549A1 (en) Dp antagonist
CY1123880T1 (el) Καινοτομοι 5-ητ2 ανταγωνιστες
BR112021025179A2 (pt) Antagonistas 5 ht2 tricíclicos
BR112021014406A2 (pt) Derivados de tiazolopiridina como antagonistas de receptor de adenosina
BR112012026509A2 (pt) "novos derivados de benzamida"
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]